We measured NFκB activation using a DNA-binding assay for p50, p52, p65, Rel-B and c-Rel in the GCB-DLBCL cell lines OCI-Ly1, OCI-Ly7, SU-DHL6 and the ABC-DLBCL cell line HBL-1 (as control), baseline and after bortezomib and MLN4924 treatment. This evidence concerns the gene NFKB1 and aneurysmal bone cyst.